Gilead Sciences, Inc. (GILD)
| Market Cap | 95.94B |
| Revenue (ttm) | 27.45B |
| Net Income (ttm) | 484.00M |
| Shares Out | 1.25B |
| EPS (ttm) | 0.35 |
| PE Ratio | 220.03 |
| Forward PE | 10.80 |
| Dividend | $3.08 (4.00%) |
| Ex-Dividend Date | Jun 14, 2024 |
| Volume | 7,448,763 |
| Open | 76.03 |
| Previous Close | 76.51 |
| Day's Range | 75.74 - 78.29 |
| 52-Week Range | 62.07 - 87.87 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 82.81 (+7.53%) |
| Earnings Date | Aug 8, 2024 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2023, GILD's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $82.81, which is an increase of 7.53% from the latest price.
News
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August ...
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of key data from its innovative HIV treatment portfolio and research pipeline, including a b...
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced full efficacy and safety results from its pivotal, Phase 3 PURPOSE 1 trial. Detailed data from the trial's in...
AHF Press Conference: Advocates Demand Gilead to Put Lives Before Profits at AIDS 2024
MUNICH--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) will host an in-person and virtual press conference at the AHF booth (#111) during the 2024 International AIDS Conference (AIDS 2024) on Tuesd...
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief Medical Officer Merdad Parsey, MD, PhD, will leave the company early next year. While the company ...
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its program for the upcoming 25th International AIDS Conference (AIDS 2024), taking place in Munich, Germany,...
Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data
Gilead Sciences (GILD) shares climbed in intraday trading Monday after Raymond James analysts upgraded the drug developer to “outperform” from “market perform.”
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash ...
Final Trades: Keurig Dr Pepper, Gilead, BlackRock & JEPQ
The Investment Committee discuss their top stocks to watch for the second half.
Gilead Stock Surges on Strong Results in HIV Drug Study
Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in wome...
Gilead's twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.
Gilead's HIV prevention treatment found 100% effective in late-stage trial
Gilead Sciences Inc.'s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
Gilead's long-acting HIV drug superior to daily pill Truvada in study
Gilead Sciences said on Thursday a late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women compared to the company's existing daily pill Truva...
Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company'...
Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game.
A success would be a gamechanger for the biotech company known for its HIV treatments.
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large...
Law Firms Speaking Out For The Thousands of California HIV Patients They Represent After Gilead's $40 Million Settlement Prompts Moral Reckoning for the HIV Community
Grant & Eisenhofer, Jenner Law, Burg Simpson, and The Lawrence Law Firm are jointly issuing the following public statement following Gilead's June 4th press release reported in the San Francisco Chron...
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from the Phase 2b MYR204 open-label study assessing the efficacy and safety of the first-in-class entry ...
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing AS...
Kite's Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced updated, four-year overall survival (OS) data from the pivotal ZUMA-3 study evaluating the CAR T-cell ther...
Encouraging New Data Presented on Kite's Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabtag...
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 stud...
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced longer-term efficacy and safety results from Arm A...
Gilead's Trodelvy extends lung cancer survival by just 1.3 months in trial
Gilead Sciences' Trodelvy improved survival by 1.3 months more than chemotherapy in previously treated patients with advanced lung cancer in a late-stage trial, a difference that was not statistically...
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA...